Publication Information

{'id': 'https://openalex.org/W3009303986', 'doi': 'https://doi.org/10.1158/1538-7445.sabcs19-pd1-03', 'title': 'Abstract PD1-03: A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial', 'display_name': 'Abstract PD1-03: A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial', 'publication_year': 2020, 'publication_date': '2020-02-15', 'ids': {'openalex': 'https://openalex.org/W3009303986', 'doi': 'https://doi.org/10.1158/1538-7445.sabcs19-pd1-03', 'mag': '3009303986'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1538-7445.sabcs19-pd1-03', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S168522863', 'display_name': 'Cancer Research', 'issn_l': '0008-5472', 'issn': ['0008-5472', '1538-7445'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5068864435', 'display_name': 'Yukinori Ozaki', 'orcid': 'https://orcid.org/0000-0002-8064-648X'}, 'institutions': [{'id': 'https://openalex.org/I4210166463', 'display_name': 'Toranomon Hospital', 'ror': 'https://ror.org/05rkz5e28', 'country_code': 'JP', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210166463']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Yukinori Ozaki', 'raw_affiliation_strings': ['1Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan'], 'affiliations': [{'raw_affiliation_string': '1Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan', 'institution_ids': ['https://openalex.org/I4210166463']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5030591160', 'display_name': 'Toru Mukohara', 'orcid': 'https://orcid.org/0000-0002-8573-418X'}, 'institutions': [{'id': 'https://openalex.org/I4210145079', 'display_name': 'National Cancer Center Hospital East', 'ror': 'https://ror.org/03rm3gk43', 'country_code': 'JP', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210145079']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Toru Mukohara', 'raw_affiliation_strings': ['2Department of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan'], 'affiliations': [{'raw_affiliation_string': '2Department of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan', 'institution_ids': ['https://openalex.org/I4210145079']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5012322249', 'display_name': 'Junji Tsurutani', 'orcid': 'https://orcid.org/0000-0002-6260-6943'}, 'institutions': [{'id': 'https://openalex.org/I119182057', 'display_name': 'Showa University', 'ror': 'https://ror.org/04mzk4q39', 'country_code': 'JP', 'type': 'education', 'lineage': ['https://openalex.org/I119182057']}, {'id': 'https://openalex.org/I916559398', 'display_name': 'Kindai University', 'ror': 'https://ror.org/05kt9ap64', 'country_code': 'JP', 'type': 'education', 'lineage': ['https://openalex.org/I916559398']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Junji Tsurutani', 'raw_affiliation_strings': ['3Advanced Cancer Translational Research Institute, Showa University, Department of Medical Oncology, Kindai University, Tokyo, Osaka, Japan'], 'affiliations': [{'raw_affiliation_string': '3Advanced Cancer Translational Research Institute, Showa University, Department of Medical Oncology, Kindai University, Tokyo, Osaka, Japan', 'institution_ids': ['https://openalex.org/I119182057', 'https://openalex.org/I916559398']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5008946028', 'display_name': 'Masato Takahashi', 'orcid': 'https://orcid.org/0000-0002-6641-9598'}, 'institutions': [{'id': 'https://openalex.org/I4210141669', 'display_name': 'Hokkaido University Hospital', 'ror': 'https://ror.org/0419drx70', 'country_code': 'JP', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210141669']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Masato Takahashi', 'raw_affiliation_strings': ['4Department of Breast Surgery, NHO Hokkaido Cancer Center, Hokkaido, Japan'], 'affiliations': [{'raw_affiliation_string': '4Department of Breast Surgery, NHO Hokkaido Cancer Center, Hokkaido, Japan', 'institution_ids': ['https://openalex.org/I4210141669']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5072348132', 'display_name': 'Koji Matsumoto', 'orcid': 'https://orcid.org/0000-0003-1907-0247'}, 'institutions': [{'id': 'https://openalex.org/I4210164148', 'display_name': 'Hyogo Prefectural Cancer Center', 'ror': 'https://ror.org/054z08865', 'country_code': 'JP', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210164148']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Koji Matsumoto', 'raw_affiliation_strings': ['5Department of Medical Oncology, Hyogo Cancer Center, Hyogo, Japan'], 'affiliations': [{'raw_affiliation_string': '5Department of Medical Oncology, Hyogo Cancer Center, Hyogo, Japan', 'institution_ids': ['https://openalex.org/I4210164148']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5067561532', 'display_name': 'Manabu Futamura', 'orcid': 'https://orcid.org/0000-0001-5622-8352'}, 'institutions': [{'id': 'https://openalex.org/I42405503', 'display_name': 'Gifu University', 'ror': 'https://ror.org/024exxj48', 'country_code': 'JP', 'type': 'education', 'lineage': ['https://openalex.org/I42405503']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Manabu Futamura', 'raw_affiliation_strings': ['6Department of Surgical Oncology, Graduate School of Medicine, Gifu University, Gifu, Japan'], 'affiliations': [{'raw_affiliation_string': '6Department of Surgical Oncology, Graduate School of Medicine, Gifu University, Gifu, Japan', 'institution_ids': ['https://openalex.org/I42405503']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5067189124', 'display_name': 'Norikazu Masuda', 'orcid': 'https://orcid.org/0000-0002-7302-0278'}, 'institutions': [{'id': 'https://openalex.org/I4210090372', 'display_name': 'Osaka National Hospital', 'ror': 'https://ror.org/00b6s9f18', 'country_code': 'JP', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210090372', 'https://openalex.org/I4210137409']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Norikazu Masuda', 'raw_affiliation_strings': ['7Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan'], 'affiliations': [{'raw_affiliation_string': '7Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan', 'institution_ids': ['https://openalex.org/I4210090372']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5015229603', 'display_name': 'Shigehisa Kitano', 'orcid': 'https://orcid.org/0000-0002-4041-8298'}, 'institutions': [], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Shigehisa Kitano', 'raw_affiliation_strings': ['8Division of Cancer Immunotherapy, Department of Experimental Therapeutics, National Cancer Center Hospital, Tsukiji, Tokyo, Japan'], 'affiliations': [{'raw_affiliation_string': '8Division of Cancer Immunotherapy, Department of Experimental Therapeutics, National Cancer Center Hospital, Tsukiji, Tokyo, Japan', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5044214575', 'display_name': 'Kenichi Yoshimura', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210104330', 'display_name': 'Kanazawa University Hospital', 'ror': 'https://ror.org/00xsdn005', 'country_code': 'JP', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210104330']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Kenichi Yoshimura', 'raw_affiliation_strings': ['9Innovative Clinical Research Center, Kanazawa University Hospital, Takara-machi, Kanazawa, Ishikawa, Japan'], 'affiliations': [{'raw_affiliation_string': '9Innovative Clinical Research Center, Kanazawa University Hospital, Takara-machi, Kanazawa, Ishikawa, Japan', 'institution_ids': ['https://openalex.org/I4210104330']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5089137663', 'display_name': 'Hironobu Minami', 'orcid': 'https://orcid.org/0000-0001-8630-9145'}, 'institutions': [{'id': 'https://openalex.org/I65837984', 'display_name': 'Kobe University', 'ror': 'https://ror.org/03tgsfw79', 'country_code': 'JP', 'type': 'education', 'lineage': ['https://openalex.org/I65837984']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Hironobu Minami', 'raw_affiliation_strings': ['10Medical Oncology/Hematology, Internal Medicine, Kobe University School of Medicine, Hyogo, Japan'], 'affiliations': [{'raw_affiliation_string': '10Medical Oncology/Hematology, Internal Medicine, Kobe University School of Medicine, Hyogo, Japan', 'institution_ids': ['https://openalex.org/I65837984']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5041726660', 'display_name': 'Toshimi Takano', 'orcid': 'https://orcid.org/0000-0002-8417-5291'}, 'institutions': [{'id': 'https://openalex.org/I4210166463', 'display_name': 'Toranomon Hospital', 'ror': 'https://ror.org/05rkz5e28', 'country_code': 'JP', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210166463']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Toshimi Takano', 'raw_affiliation_strings': ['1Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan'], 'affiliations': [{'raw_affiliation_string': '1Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan', 'institution_ids': ['https://openalex.org/I4210166463']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 10, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 2.285, 'has_fulltext': False, 'cited_by_count': 17, 'citation_normalized_percentile': {'value': 0.999975, 'is_in_top_1_percent': True, 'is_in_top_10_percent': True}, 'cited_by_percentile_year': {'min': 91, 'max': 92}, 'biblio': {'volume': '80', 'issue': '4_Supplement', 'first_page': 'PD1', 'last_page': '03'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T12829', 'display_name': 'Advanced Breast Cancer Therapies', 'score': 0.9985, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T12829', 'display_name': 'Advanced Breast Cancer Therapies', 'score': 0.9985, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10158', 'display_name': 'Cancer Immunotherapy and Biomarkers', 'score': 0.9966, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11914', 'display_name': 'PARP inhibition in cancer therapy', 'score': 0.9599, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/clinical-endpoint', 'display_name': 'Clinical endpoint', 'score': 0.70887315}, {'id': 'https://openalex.org/keywords/combination-therapy', 'display_name': 'Combination therapy', 'score': 0.5021689}, {'id': 'https://openalex.org/keywords/triple-negative-breast-cancer', 'display_name': 'Triple-negative breast cancer', 'score': 0.49599513}, {'id': 'https://openalex.org/keywords/progression-free-survival', 'display_name': 'Progression-free survival', 'score': 0.44118577}], 'concepts': [{'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.90359294}, {'id': 'https://openalex.org/C2777802072', 'wikidata': 'https://www.wikidata.org/wiki/Q413299', 'display_name': 'Bevacizumab', 'level': 3, 'score': 0.8466445}, {'id': 'https://openalex.org/C2775930923', 'wikidata': 'https://www.wikidata.org/wiki/Q12859063', 'display_name': 'Metastatic breast cancer', 'level': 4, 'score': 0.7504474}, {'id': 'https://openalex.org/C203092338', 'wikidata': 'https://www.wikidata.org/wiki/Q1340863', 'display_name': 'Clinical endpoint', 'level': 3, 'score': 0.70887315}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.66172713}, {'id': 'https://openalex.org/C2780030458', 'wikidata': 'https://www.wikidata.org/wiki/Q7041828', 'display_name': 'Nivolumab', 'level': 4, 'score': 0.6187676}, {'id': 'https://openalex.org/C530470458', 'wikidata': 'https://www.wikidata.org/wiki/Q128581', 'display_name': 'Breast cancer', 'level': 3, 'score': 0.61086}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.601439}, {'id': 'https://openalex.org/C2777292972', 'wikidata': 'https://www.wikidata.org/wiki/Q423762', 'display_name': 'Paclitaxel', 'level': 3, 'score': 0.5589694}, {'id': 'https://openalex.org/C2776999253', 'wikidata': 'https://www.wikidata.org/wiki/Q1304270', 'display_name': 'Combination therapy', 'level': 2, 'score': 0.5021689}, {'id': 'https://openalex.org/C2780110267', 'wikidata': 'https://www.wikidata.org/wiki/Q7843332', 'display_name': 'Triple-negative breast cancer', 'level': 4, 'score': 0.49599513}, {'id': 'https://openalex.org/C31760486', 'wikidata': 'https://www.wikidata.org/wiki/Q7180990', 'display_name': 'Phases of clinical research', 'level': 3, 'score': 0.48359817}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.45415676}, {'id': 'https://openalex.org/C2780739268', 'wikidata': 'https://www.wikidata.org/wiki/Q2112244', 'display_name': 'Progression-free survival', 'level': 3, 'score': 0.44118577}, {'id': 'https://openalex.org/C2777063308', 'wikidata': 'https://www.wikidata.org/wiki/Q1435822', 'display_name': 'Neutropenia', 'level': 3, 'score': 0.41807243}, {'id': 'https://openalex.org/C29730261', 'wikidata': 'https://www.wikidata.org/wiki/Q274160', 'display_name': 'Toxicity', 'level': 2, 'score': 0.32961255}, {'id': 'https://openalex.org/C2776694085', 'wikidata': 'https://www.wikidata.org/wiki/Q974135', 'display_name': 'Chemotherapy', 'level': 2, 'score': 0.32514274}, {'id': 'https://openalex.org/C535046627', 'wikidata': 'https://www.wikidata.org/wiki/Q30612', 'display_name': 'Clinical trial', 'level': 2, 'score': 0.3248034}, {'id': 'https://openalex.org/C2777701055', 'wikidata': 'https://www.wikidata.org/wiki/Q1427096', 'display_name': 'Immunotherapy', 'level': 3, 'score': 0.104186535}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1538-7445.sabcs19-pd1-03', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S168522863', 'display_name': 'Cancer Research', 'issn_l': '0008-5472', 'issn': ['0008-5472', '1538-7445'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'score': 0.85, 'display_name': 'Good health and well-being', 'id': 'https://metadata.un.org/sdg/3'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W4302291056', 'https://openalex.org/W4283527516', 'https://openalex.org/W3009303986', 'https://openalex.org/W2806126121', 'https://openalex.org/W2589008114', 'https://openalex.org/W2441572282', 'https://openalex.org/W2163003060', 'https://openalex.org/W2091442233', 'https://openalex.org/W2077649377', 'https://openalex.org/W2033027303'], 'abstract_inverted_index': {'Abstract': [0], 'Background:': [1], 'PD-1': [2], 'inhibitors': [3], 'have': [4], 'been': [5], 'developed': [6], 'for': [7, 48, 81, 402, 408], 'various': [8], 'cancer': [9, 51, 204, 226, 410], 'types,': [10], 'including': [11], 'breast': [12, 50, 203, 225, 409, 507], 'cancer.': [13], 'Potential': [14], 'synergistic': [15], 'effects': [16], 'of': [17, 41, 69, 170, 243, 292, 302, 314, 322, 334, 347, 389, 490, 515], 'nivolumab,': [18], 'paclitaxel': [19, 44, 72, 95, 394, 493], 'and': [20, 39, 67, 102, 147, 152, 157, 160, 195, 213, 227, 246, 261, 300, 320, 353, 367], 'bevacizumab': [21, 46, 74, 103, 396, 495], 'in': [22, 26, 221, 230, 391, 502], 'combination': [23, 75, 392], 'was': [24, 211, 215, 218, 236, 252, 258, 267, 343], 'reported': [25], 'preclinical': [27], 'models.': [28], 'Therefore,': [29], 'we': [30], 'initiated': [31], 'this': [32], 'investigator-initiated': [33], 'trial': [34, 415, 419, 511], 'to': [35, 63, 165, 177], 'evaluate': [36, 64], 'the': [37, 65, 123, 148, 279, 328, 377, 382, 386, 488, 516], 'efficacy': [38, 66, 388, 489], 'safety': [40, 68], 'nivolumab': [42, 70, 88, 491], '+': [43, 45, 71, 73], 'therapy': [47, 76, 497], 'metastatic': [49, 506], '(MBC)': [52], 'patients': [53, 162, 503], '(pts).Methods:': [54], 'This': [55, 380, 405, 418], 'is': [56, 122, 381, 420], 'a': [57, 78, 167, 398, 499], 'Phase': [58], 'II,': [59], 'multi-center,': [60], 'single-arm': [61], 'study': [62, 384, 486], 'as': [77, 397, 498], 'first-line': [79, 500], 'treatment': [80, 277, 401, 501], 'pts': [82, 184, 188, 197, 222, 231, 272, 287, 293, 303, 315, 323, 329], 'with': [83, 191, 200, 223, 232, 239, 330, 356, 393, 504], 'HER2—': [84, 182, 403], 'MBC.': [85, 404], 'Patients': [86], 'received': [87], '240': [89], 'mg/body': [90], 'on': [91, 98, 106, 208, 359], 'day': [92], '1,': [93], '15,': [94, 101], '90': [96], 'mg/m2': [97], 'day1,': [99, 107], '8,': [100], '10': [104], 'mg/kg': [105], '15': [108], 'every': [109], '4': [110, 298, 308], 'weeks': [111], 'until': [112], 'disease': [113, 136, 435, 440], 'progression': [114, 141], 'or': [115, 297, 307], 'intolerable': [116], 'toxicity': [117], 'experienced.': [118], 'The': [119, 150], 'primary': [120], 'endpoint': [121, 346], 'objective': [124], 'response': [125, 430, 445], 'rate': [126, 138, 248, 263, 446, 452], '(ORR)': [127], 'by': [128, 349, 364, 370, 422], 'independent': [129, 350], 'central': [130, 351], 'assessment.': [131], 'Key': [132], 'secondary': [133], 'endpoints': [134], 'include': [135], 'control': [137, 451], '(DCR:': [139], 'CR+PR+SD),': [140], 'free': [142], 'survival': [143], '(PFS),': [144], 'overall': [145], 'survival,': [146], 'toxicity.': [149], 'threshold': [151], 'expected': [153], 'ORR': [154, 206, 217, 348], 'are': [155, 163], '55%': [156], '70%,': [158], 'respectively,': [159], '47': [161], 'needed': [164], 'ensure': [166], 'statistical': [168], 'power': [169], '80%': [171], '(α=0.10).': [172], 'Results:': [173], 'From': [174], 'February': [175], '2018': [176], 'October': [178], '2018,': [179], '57': [180], 'female': [181], 'MBC': [183], 'were': [185, 190, 199, 274], 'enrolled.': [186], 'Thirty-nine': [187], '(68%)': [189], 'hormone': [192], 'receptor-positive': [193], '(HR+),': [194], '18': [196], '(32%)': [198], 'triple': [201], 'negative': [202], '(TNBC).': [205], 'based': [207], 'investigator': [209], 'assessment': [210, 352], '75.4%,': [212], 'DCR': [214], '96.4%.': [216], '71.7%': [219], '(28/39)': [220], 'HR+': [224], '83.3%': [228], '(15/18)': [229], 'TNBC.': [233], 'Median': [234, 256], 'PFS': [235, 247], 'not': [237, 259], 'reached': [238, 260], 'median': [240], 'follow-up': [241], 'time': [242], '10.7': [244], 'months,': [245], 'at': [249, 264, 278, 376], '12': [250, 265], 'months': [251, 266], '75.8%': [253], '(95%CI:': [254, 269], '60.9-86.2).': [255], 'OS': [257, 262], '87.1%': [268], '70.7-94.9).': [270], 'Thirty-five': [271], '(59%)': [273], 'still': [275], 'under': [276], 'data': [280], 'cut-off': [281], 'date': [282], '(1st': [283], 'June': [284], '2019).': [285], 'All': [286], 'had': [288, 294, 304, 316, 324, 336], '≥1': [289], 'AE;': [290], '58%': [291], 'Grade': [295, 305], '3': [296, 306], 'AEs': [299, 318], '17%': [301], 'immune': [309], 'related-AEs.': [310], 'Twenty': [311], 'two': [312], 'percent': [313], 'serious': [317], '(SAE),': [319], '12%': [321], 'nivolumab-related': [325, 331], 'SAEs.': [326, 339], 'Among': [327], 'SAEs,': [332], '71%': [333], 'them': [335], 'recovered': [337], 'from': [338], 'No': [340], 'treatment-related': [341], 'death': [342], 'observed.': [344], 'Primary': [345], 'subset': [354], 'analysis': [355], 'PD-L1': [357], 'expression': [358], 'tumor': [360], 'tissue': [361], '(CPS,': [362], 'TPS': [363], '28-8': [365], 'antibody': [366], 'IC,': [368], 'TC': [369], 'SP142': [371], 'antibody)': [372], 'will': [373], 'be': [374], 'presented': [375], 'symposium.': [378], 'Conclusions:': [379], 'first': [383, 399], 'showing': [385], 'promising': [387], 'Nivolumab': [390], 'plus': [395, 492, 494], 'line': [400], 'triple-combination': [406, 496], 'strategy': [407], 'warrants': [411], 'further': [412], 'study.': [413], 'Clinical': [414], 'information:': [416], 'UMIN000030242.Funding:': [417], 'sponsored': [421], 'Ono': [423], 'pharmaceutical': [424], 'company.': [425], 'ResponseTotal100%': [426], '(N': [427, 432, 437, 442, 448, 455], '=': [428, 433, 438, 443, 449, 456], '57)Partial': [429], '(PR)75.4%': [431], '43)Stable': [434], '(SD)21.1%': [436], '12)Progressive': [439], '(PD)1.7%': [441], '1)Objective': [444], '(ORR)75.4%': [447], '43)Disease': [450], '(DCR)': [453], ':CR+PR+SD96.4%': [454], '55)': [457], 'Citation': [458], 'Format:': [459], 'Yukinori': [460], 'Ozaki,': [461], 'Toru': [462], 'Mukohara,': [463], 'Junji': [464], 'Tsurutani,': [465], 'Masato': [466], 'Takahashi,': [467], 'Koji': [468], 'Matsumoto,': [469], 'Manabu': [470], 'Futamura,': [471], 'Norikazu': [472], 'Masuda,': [473], 'Shigehisa': [474], 'Kitano,': [475], 'Kenichi': [476], 'Yoshimura,': [477], 'Hironobu': [478], 'Minami,': [479], 'Toshimi': [480], 'Takano.': [481], 'A': [482], 'multicenter': [483], 'phase': [484], 'II': [485], 'evaluating': [487], 'HER2-negative': [505], 'cancer:': [508], 'WJOG9917B': [509], 'NEWBEAT': [510], '[abstract].': [512], 'In:': [513], 'Proceedings': [514], '2019': [517, 523], 'San': [518, 526], 'Antonio': [519], 'Breast': [520], 'Cancer': [521, 532], 'Symposium;': [522], 'Dec': [524], '10-14;': [525], 'Antonio,': [527], 'TX.': [528], 'Philadelphia': [529], '(PA):': [530], 'AACR;': [531], 'Res': [533], '2020;80(4': [534], 'Suppl):Abstract': [535], 'nr': [536], 'PD1-03.': [537]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W3009303986', 'counts_by_year': [{'year': 2024, 'cited_by_count': 1}, {'year': 2023, 'cited_by_count': 2}, {'year': 2022, 'cited_by_count': 5}, {'year': 2021, 'cited_by_count': 8}, {'year': 2020, 'cited_by_count': 1}], 'updated_date': '2024-12-24T07:26:22.707895', 'created_date': '2020-03-13'}